Adaptive Biotechnologies Corporation (ADPT)

Adaptive Biotechnologies Revenue

Adaptive Biotechnologies had revenue of $71.55M in the quarter ending June 30, 2026, with 21.53% growth. This brings the company's total for the last twelve months to $308.08M, up 50.13% year-over-year. In the year 2025, Adaptive Biotechnologies had annual revenue of $276.98M with 54.77% growth. That makes Adaptive Biotechnologies the 14,342nd largest company in the world by revenue and 2,604th in the United States.

• Revenue (ttm): $308.08M
• Revenue Growth: +50.13%
• P/S Ratio: 12.46
• Revenue / Employee: $493,720
• Employees: 624
• Market Cap: 3.82B

Revenue Chart

Chart

Chart

Revenue by Segment

Chart

• Minimal Residual Disease (MRD) 212.33M 76.7%
• Immune Medicine 64.64M 23.3%

Fiscal year ended Dec 31, 2025 See the full Adaptive Biotechnologies breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	276.98M	98.02M	54.77%
Dec 31, 2024	178.96M	8.68M	5.10%
Dec 31, 2023	170.28M	-15.03M	-8.11%
Dec 31, 2022	185.31M	30.96M	20.06%
Dec 31, 2021	154.34M	55.96M	56.88%
Dec 31, 2020	98.38M	13.31M	15.65%
Dec 31, 2019	85.07M	29.41M	52.83%
Dec 31, 2018	55.66M	17.22M	44.77%
Dec 31, 2017	38.45M	-	-

Data Sources: Fiscal.ai and S&P Global Market Intelligence Last updated: Aug 4, 2026

Revenue data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company. Revenue segment data is provided by S&P Global Market Intelligence.

Update frequency:

Quarterly

Last checked:

Oct 17, 2026

Data Sources Report a data error